SL
ADCT icon

Siren LLC’s ADC Therapeutics ADCT Stock Holding History

Siren LLC’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,163,461
Closed -$3.66M – 119
2024
Q3 		$3.66M Buy
+1,163,461
New +$3.67M 0.18% 74

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Siren LLC's ADCT Position: Q4 2024 in Review

Siren LLC sold out of ADC Therapeutics (ADCT) in Q4 2024, closing a stake of 1,163,461 shares — an estimated $3.66M sold.

Siren LLC first reported a position in ADCT in Q3 2024 and held it in 1 quarter. The position peaked at $3.66M in Q3 2024. 83 funds tracked by Wall St. Rank hold ADCT as of Q4 2024.

  • Siren LLC reported no remaining ADC Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Siren LLC sold 1,163,461 ADC Therapeutics shares in Q4 2024, an estimated $3.66M.
  • Siren LLC first reported a position in ADC Therapeutics in Q3 2024 and held it in 1 quarter.
  • Siren LLC's ADC Therapeutics position peaked at $3.66M in Q3 2024.
  • 83 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2024.

Based on Siren LLC's 13F filing for Q4 2024, filed 14 Feb 2025.